Gilead/Kite to acquire next generation CAR-T therapyDecember 20, 2022 - Kite, a Gilead Company (Nasdaq: GILD), and Tmunity Therapeutics (Tmunity), today announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.
https://www.gilead.com/news-and-press/press-room/press-releases/2022/12/kite-to-acquire-tmunity-therapeutics-to-pursue-next-generation-car-t-cell-therapy-advancements-in-cancer
Relatedly - ONCY's oncolytic virus-prelareorep mediated expansion of dual-specific CAR T cells improved treatment efficacy against solid tumors that effectively was viewed as a "cure" when administered systematically and in combination with one another followed by a pelareorep "boost".